First Light Asset Management, LLC Nektar Therapeutics Transaction History

First Light Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $12.1 Million - $25.9 Million	-713,769 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $1.54 Million - $1.8 Million	-49,634 Reduced 6.5%	713,769 $25.4 Million
Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $1.05 Million - $1.54 Million	33,177 Added 4.54%	763,403 $25.7 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $10.9 Million - $20.3 Million	357,675 Added 96.01%	730,226 $24 Million
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $78,982 - $116,432	-1,700 Reduced 0.45%	372,551 $22.7 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $3.43 Million - $7.75 Million	74,165 Added 24.71%	374,251 $18.3 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $2.96 Million - $5.6 Million	-51,655 Reduced 14.69%	300,086 $31.9 Million
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $3.49 Million - $9.16 Million	-151,452 Reduced 30.1%	351,741 $21 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $587,052 - $791,976	32,999 Added 7.02%	503,193 $12.1 Million
Q2 2017 Aug 14, 2017	BUY	N/A	470,194	470,194 $9.19 Million

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on First Light Asset Management, LLC with notifications on news.